Russell Investments Group
SYRE icon

Russell Investments Group’s Spyre Therapeutics SYRE Stock Holding History

Russell Investments Group’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12M Buy
134,757
+124,826
+1,257% +$9.11M 0.01% 968
2026
Q1 		$501K Buy
9,931
+4,377
+79% +$165K ﹤0.01% 2502
2025
Q4 		$182K Buy
5,554
+1,320
+31% +$34.5K ﹤0.01% 2877
2025
Q3 		$71K Buy
4,234
+4,092
+2,882% +$66.7K ﹤0.01% 3148
2025
Q2 		$2.13K Buy
+142
New +$2.1K ﹤0.01% 3583
2024
Q4 		– Sell
-129
Closed -$3.79K – 3788
2024
Q3 		$3.79K Buy
+129
New +$3.59K ﹤0.01% 3273
2022
Q2 		– Sell
-120
Closed -$6K – 2962
2022
Q1 		$6K Hold
120
– – ﹤0.01% 2726
2021
Q4 		$14K Hold
120
– – ﹤0.01% 2966
2021
Q3 		$23K Sell
120
-841
-88% -$147K ﹤0.01% 2992
2021
Q2 		$165K Sell
961
-2,418
-72% -$439K ﹤0.01% 2957
2021
Q1 		$668K Sell
3,379
-2,261
-40% -$434K ﹤0.01% 2400
2020
Q4 		$1.11M Sell
5,640
-981
-15% -$203K ﹤0.01% 2076
2020
Q3 		$1.17M Buy
6,621
+4,007
+153% +$741K ﹤0.01% 1992
2020
Q2 		$603K Buy
2,614
+114
+5% +$21.7K ﹤0.01% 2305
2020
Q1 		$290K Sell
2,500
-3,594
-59% -$611K ﹤0.01% 2412
2019
Q4 		$1.16M Hold
6,094
– – ﹤0.01% 2032
2019
Q3 		$1.17M Buy
6,094
+6,078
+37,988% +$1.18M ﹤0.01% 1937
2019
Q2 		$3K Buy
+16
New +$2.77K ﹤0.01% 2838

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Russell Investments Group's SYRE Position: Q2 2026 in Review

Russell Investments Group increased its Spyre Therapeutics (SYRE) stake by 1,257% in Q2 2026, buying an estimated $9.11M and bringing the position to 134,757 shares worth $12M. The position accounts for 0.01% of the portfolio, ranked #968.

Russell Investments Group first reported a position in SYRE in Q2 2019 and has held it in 18 quarters since. 265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • Russell Investments Group held 134,757 shares of Spyre Therapeutics worth $12M as of Q2 2026.
  • Russell Investments Group bought 124,826 Spyre Therapeutics shares in Q2 2026, an estimated $9.11M.
  • Spyre Therapeutics made up 0.01% of Russell Investments Group's portfolio in Q2 2026, its #968 holding.
  • Russell Investments Group first reported a position in Spyre Therapeutics in Q2 2019 and has held it in 18 quarters since.
  • 265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Russell Investments Group's 13F filing for Q2 2026, filed 6 Aug 2026.